Status:

RECRUITING

PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer

Lead Sponsor:

Azienda Ospedaliera Universitaria Integrata Verona

Conditions:

Oligometastatic Gastric Adenocarcinoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Peritoneal Carcinomatosis is the most frequent site of metastases observed in patients with gastric cancer. Current standard treatment for these patients is palliative systemic chemotherapy, but the p...

Detailed Description

This is a prospective, open label, randomized multicenter phase III clinical study that aims to evaluate the effects of PIPAC combined with systemic chemotherapy vs. intravenous systemic chemotherapy ...

Eligibility Criteria

Inclusion

  • Primary resectable gastric cancer with positive peritoneal cytology and/or low burden peritoneal metastases (PCI ≤6) confirmed by laparoscopy
  • Signature of written informed consent
  • ECOG PS 0-1

Exclusion

  • Extraperitoneal metastases
  • PCI \>6
  • Gastro-esophageal junction tumor of esophageal relevance (Siewert I-II)
  • Previous allergic reactions to cisplatin or doxorubicin
  • Hemorrhagic or occlusive manifestation of the primary tumor with palliative surgery needed
  • ASA IV
  • Positivity for EBV, MSI and HER2 on diagnostic biopsies
  • Pregnancy and breastfeeding
  • Contraindication to any drug contained in the chemotherapy regimen
  • Hepatic impairment (AST/ALT\> 3 times normal values, ALT\>3 times normal values, Bilirubin\>1.5 normal values)
  • Ischemic/hemorrhagic stroke in the last 6 months
  • Acute myocardial infarction in the last 6 months
  • Moderate/severe heart failure (NYHA III-IV)
  • Leukopenia\< 2,000/μl
  • Thrombocytopenia \< 100,000/μl
  • Active hepatitis B or C
  • HIV infection
  • Creatinine clearance less than 30 ml/min

Key Trial Info

Start Date :

March 31 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2028

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT05303714

Start Date

March 31 2022

End Date

September 30 2028

Last Update

February 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

AOUI Verona

Verona, Italy, 37126